Simon Moroney

Presidente presso BIOTALYS NV

Patrimonio netto: 581 789 $ in data 30/04/2024

65 anni

97 relazioni

Consumer Services

Health Technology

Government

Profilo

Simon E.
Moroney was the founder of MorphoSys AG, a company founded in 1992, where he held the title of Chief Executive Officer from 1992 to 2019.
He is currently Vice Chairman at Novartis AG since 2020 and Chairman at Biotalys NV since 2021.
In his former positions, he served as Director-Supervisory Board at ProtAffin Biotechnologie AG from 2009 to 2011, and as President at the Government of Germany.
He also worked as a Research Associate at the University of Cambridge from 1991 to 1992, as an Assistant Professor at the University of British Columbia, as an Associate in the Chemistry Department at the Swiss Federal Institute of Technology from 1986 to 1989, and as an Associate at Harvard Medical School from 1984 to 1986.
Dr. Moroney obtained a doctorate degree from the University of Oxford in 1984 and a graduate degree from Waikato University in 1981.

Partecipazioni note in società pubbliche

Società	Data	Numero di azioni	Valorizzazione	Data di valutazione
NOVARTIS AG 0.00%	31/12/2023	5 992 ( 0.00% )	581 789 $	30/04/2024

Posizioni attive di Simon Moroney

Società	Posizione	Inizio
NOVARTIS AG	Direttore/Membro del Consiglio	28/02/2020
BIOTALYS NV	Presidente	01/04/2021

Tutte le posizioni attive di Simon Moroney

Precedenti posizioni note di Simon Moroney

Società	Posizione	Fine
MORPHOSYS AG	Amministratore Delegato	01/09/2019
ProtAffin Biotechnologie AG ProtAffin Biotechnologie AG Pharmaceuticals: MajorHealth Technology ProtAffin was spun out of the Karl-Franzens University of Graz in July 2005. The company currently employs 16 people in modern office and laboratory facilities in Graz and Vienna and plans to expand to 27 by the end of 2009. They are well financed by a syndicate of 5 international venture capital investors. The company has a balanced 'platform-product' strategy: a lead compound in pre-clinical development and a core discovery technology by which they are supporting a sustainable pipeline of products via its unique CellJammer® discovery technology platform. ProtAffin is leveraging its leading technical expertise in protein-glycan interactions to develop novel biological products. They are currently collaborating with a number of university groups in Austria, Germany, Brazil and the UK. They plan to collaborate with Pharma and Biotech companies interested to access its technology for the development of novel anti-inflammatory products with a unique mechanism of action.	Direttore/Membro del Consiglio	17/02/2014
University of Cambridge	Corporate Officer/Principal	01/01/1992
Swiss Federal Institute of Technology	Corporate Officer/Principal	01/01/1989
Harvard Medical School	Corporate Officer/Principal	01/01/1986

Vedi nel dettaglio l'esperienza di Simon Moroney

Formazione di Simon Moroney

Waikato University	Graduate Degree
University of Oxford	Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Simon Moroney

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	3
MORPHOSYS AG	Health Technology
NOVARTIS AG	Health Technology
BIOTALYS NV	Process Industries

Aziende private	2
ProtAffin Biotechnologie AG ProtAffin Biotechnologie AG Pharmaceuticals: MajorHealth Technology ProtAffin was spun out of the Karl-Franzens University of Graz in July 2005. The company currently employs 16 people in modern office and laboratory facilities in Graz and Vienna and plans to expand to 27 by the end of 2009. They are well financed by a syndicate of 5 international venture capital investors. The company has a balanced 'platform-product' strategy: a lead compound in pre-clinical development and a core discovery technology by which they are supporting a sustainable pipeline of products via its unique CellJammer® discovery technology platform. ProtAffin is leveraging its leading technical expertise in protein-glycan interactions to develop novel biological products. They are currently collaborating with a number of university groups in Austria, Germany, Brazil and the UK. They plan to collaborate with Pharma and Biotech companies interested to access its technology for the development of novel anti-inflammatory products with a unique mechanism of action.	Health Technology
Government of Germany	Government